Skip to main content

Pre-Transplant Donor Screening. Viral Load.
Genotyping. Drug Resistance.​


Test Name Test Code CPT Code(s) Specimen Type NY Approved? Volume Turnaround Time
HIV-1 Quantitative NAAT 33259 87536 Plasma Yes

2 mL (min. 1.5 mL)

7 business days from receipt of specimen

HIV-1/HIV-2 Plus O EIA 30816 86703 Plasma, Serum Yes

300 µL (min 150 µL)

Within 24 hours from receipt of specimen


Ultrio Elite HIV-1/2, HCV, HBV NAT 30805 87516, 87521, 87535 Plasma, Serum Yes

2.5 mL (min 1.5 mL)

HIV-1 Genotypic Drug Resistance Sequencing 1901 87901, 87906 Plasma Yes

2 mL (min. 1 mL/ min. viral load 600 copies/mL)

4-6 business days from receipt of specimen


HIV-1 Integrase Genotyping 1950 87906 Plasma Yes


Our HIV-1 Genotypic Drug Resistance Sequencing assay provides the fastest characterization—including subtype identification—of the most relevant viral genomic mutations known to confer resistance to antiretroviral drugs. LEARN MORE

Significant Advantages of Genotyping

  • Detects the genomic mutations known to confer resistance to antiretroviral drugs
  • Estimates susceptibility to a growing list of approved medications referenced by the preeminent, curated Stanford University HIV Drug Resistance Database (HIVDB)
  • Excludes distracting test results (often included in alternative tests) that are unrelated to HIV drug resistance
  • Delivers industry-leading turnaround time: <6 days from specimen receipt
  • Reduces delays in getting patients on appropriate medications
  • Is available via HL7 interface for efficient, streamlined reporting and convenient access to actionable information
  • Identifies HIV-1 subtypes B, A, AE, AG, C, D and G
  • Is cost-effective

When to Order HIV-1 Genotypic Drug Resistance Sequencing

Because HIV drug resistance changes over time, it is recommended that HIV testing be ordered at various stages in a patient’s journey. Consistent with NIH Guidelines, HIV testing is informative in:

  • Getting a baseline profile identifying current viral load
  • Problem-solving lack of response to therapy
  • Understanding patient deterioration
  • Getting clarification when considering a change in drug therapies

Know Your Patient's Susceptibility to Approved Antiretroviral Drugs

Genotyping estimates a patient’s susceptibility to:

  • NRTIs
  • NNRTIs
  • PIs
  • INIs

Why Advanced Subtyping Makes Our HIV Testing Most Beneficial

As new HIV strains continue to emerge* in a virus with high genetic variability, Eurofins Viracor fulfills an unmet need for HIV-1 subtyping.

  • The Genotyping test reports HIV-1 and provides susceptibility estimates for these subtypes:
        - B, A, AE, AG, C, D and G
  • Alternative tests may estimate only HIV-1 B or may not identify the subtype at all
  • B subtype is most common, but 90% of cases worldwide are non-B
  • Non-B is on the rise in the US
  • As non-B prevalence rises, the assay will deliver a growing body of knowledge about treatment


The Stanford University HIV Database Assures Testing is Current on Approved HIV Antiretroviral Drugs

A patient’s susceptibility profile is determined by Eurofins Viracor HIV-1 Genotypic Drug Resistant Sequencing test, based on the curated Stanford University HIV Drug Resistance Database. For a complete list of regions evaluated, associated susceptibility, and references, visit:

Advantages include:

  • The Stanford database lists possible mutations and also includes links to supporting literature
  • Stanford updates the database continually. Viracor incorporates the newest updates in its reporting. Physicians receive reports based on current, curated data to support drug therapy decisions
  • The database stores, analyzes, and makes publicly available HIV drug resistance data from HIV researchers and clinicians
  • Stanford helps identify gaps in drug resistance information and updates its information through retrospective or prospective studies
  • Other HIV drug resistance testing may use only a lab-developed algorithm
Type of Drug Drugs Reported
Nucleoside Reverse-Transcriptase Inhibitors (NRTI)

Abacavir (ABC),

Zidovudine (AZT),

Stavudine (D4T),

Didanosine (DDI),

Emtricitabine (FTC),

Lamivudine (3TC),

Tenofovir (TDF)

Non-Nucleoside Reverse-Transcriptase Inhibitors (NNRTI)

Doravirine (DOR),

Efavirenz (EFV),

Etravirine (ETR),

Nevirapine (NVP),

Rilpivirine (RPV)

Protease Inhibitors (PI)

Atazanavir w/ritonavir (ATV/r),

Darunavir w/ritonavir (DRV/r),

Fosamprenavir w/ritonavir (FPV/r),

Indinavir w/ritonavir (IDV/r),

Lopinavir w/ritonavir (LPV/r),

Nelfinavir (NFV),

Saquinavir w/ritonavir (SQV/r),

Tipranavir w/ritonavir (TPV/r)

Integrase Inhibitors (INI)

Bictegravir (BIC),

Dolutegravir (DTG),

Elvitegravir (EVG),

Raltegravir (RAL)


Back to top